Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

A shot in the arm for new antibiotics

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

IQVIA data from Alan Carr, Needham; FDA; CMS.


  1. Centers for Medicare and Medicaid Services. FY 2020 IPPS Final Rule, CMS-1716-F (2019);

  2. Verma, S. Aligning payment and prevention to drive antibiotic innovation for Medicare beneficiaries. Health Aff. (Millwood) (2019).

  3. Outterson, K. Innovative ways to pay for new antibiotics will help fight superbugs. STAT (2018).

  4. Wennberg, J. E., McPherson, K. & Caper, P. N. Engl. J. Med. 311, 295–300 (1984).

    Article  CAS  Google Scholar 

  5. Morrisey, M. A., Sloan, F. A. & Valvona, J. Health Aff. (Millwood) 7, 52–64 (1988).

    Article  CAS  Google Scholar 

  6. Liu, Z., Dow, W. H. & Norton, E. C. J. Health Econ. 23, 129–155 (2004).

    Article  Google Scholar 

  7. Chhabra, K. R., Ibrahim, A. M., Thumma, J. R., Ryan, A. M. & Dimick, J. B. Health Aff. (Millwood) 38, 1207–1215 (2019).

    Article  Google Scholar 

  8. Clyde, A. T., Bockstedt, L., Farkas, J. A. & Jackson, C. Health Aff. (Millwood) 27, 1632–1641 (2008).

    Article  Google Scholar 

  9. Rex, J. H. et al. Clin. Infect. Dis. 65, 141–146 (2017).

    Article  Google Scholar 

  10. Powers, J. H., Evans, S. R. & Kesselheim, A. S. Br. Med. J. 360, k587 (2018).

    Article  Google Scholar 

  11. Social Security Act §1886(a)(4) (1989).

  12. DISARM Act (2019).

  13. Ardal, C.O. et al. Revitalizing the antibiotic pipeline: stimulating innovation while driving sustainable use and global access. DRIVE-AB Final Report (European Commission, Innovative Medicines Initiative, 2018).

  14. Outterson, K. et al. PLoS Med. 13, e1002043 (2016).

    Article  Google Scholar 

  15. Outterson, K., Powers, J. H., Daniel, G. W. & McClellan, M. B. Health Aff. (Millwood) 34, 277–285 (2015).

    Article  Google Scholar 

  16. Outterson, K. Cardozo Law Rev. 31, 613 (2010).

    Google Scholar 

  17. Kesselheim, A. S. & Outterson, K. Yale J. Health Policy Law Ethics 11, 101–167 (2011).

    PubMed  Google Scholar 

  18. O’Neill, J. Tackling drug-resistant infections globally: final report and recommendations (Review on Antimicrobial Resistance, London, 2016).

    Google Scholar 

  19. Clift, C. et al. Towards a new global business model for antibiotics: report from the Chatham House Working Group on New Antibiotic Business Models (London, 2015).

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Kevin Outterson.

Ethics declarations

Competing interests

K.O. is the executive director of CARB-X, funded by three governments (US, UK and Germany) and two foundations (Wellcome Trust and Gates). CARB-X is a non-profit accelerator of preclinical and phase 1 antibacterial research that awards grants worldwide.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Outterson, K. A shot in the arm for new antibiotics. Nat Biotechnol 37, 1110–1112 (2019).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research